Digestive and Liver Disease

Papers
(The median citation count of Digestive and Liver Disease is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?73
Pharmacologic venous thromboembolism prophylaxis is not associated with post sphincterotomy bleeding after endoscopic retrograde cholangiopancreatography65
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID62
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU61
Author's Reply: “Dairy-Rich diets: A promising strategy for reducing the risk of metabolic liver disease”55
The burden of HDV infection: A ten-years’ experience of a sicilian tertiary centre of liver disease54
The potential role of machine learning in modelling advanced chronic liver disease50
Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks43
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosin-kinase inhibitors: a real-world analysis41
Isolated IgG4-related cholecystitis mimicking an advanced gallbladder cancer: Don't fall into the trap39
Factors associated with prior acute pancreatitis episodes37
Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start?36
Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly36
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study34
Evolution of hepatic encephalopathy over time: ecological data from a tertiary referral centre for hepatology31
Giant gastric myxoid epithelioid gastrointestinal stromal tumor30
Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles29
Subepithelial lesions in the distal esophagus28
[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study28
Editorial Board28
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis27
Reply to: “Inflammatory bowel disease epidemiology data from a prospective registry in Córdoba, Argentina: Raising the bar for future studies in Latin America”.27
Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients26
T.03.2 EXPLORING A NOVEL COMPOSITE DIAGNOSTIC TOOL USING NON-CONTRAST EUS ENHANCED CYST WALL MICROVASCULAR IMAGING AND CYST FLUID ANALYSIS TO DIFFERENTIATE PANCREATIC CYSTIC NEOPLASMS25
OC.10.3 LUMEN-APPOSING METAL STENTS FOR EUS-GUIDED DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS: RESULTS OF A LARGE MULTICENTER COHORT24
OC.10.8 DISHEVELLED-ASSOCIATED ANTAGONIST OF B-CATENIN 2 (DACT2) IN PANCREATIC DUCTAL ADENOCARCINOMA24
OC.09.6 PREDICTIVE VALUE OF MILAN ULTRASOUND CRITERIA IN ULCERATIVE COLITIS: A PROSPECTIVE OBSERVATIONAL COHORT STUDY23
AF.5 COMPARISON OF CORPUS MUCOSA HISTOLOGICAL PARAMETERS BETWEEN PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS AND MULTIFOCAL ATROPHIC GASTRITIS BEYOND HELICOBACTER PYLORI INFECTION23
T.03.5 EFFECT OF ENVIRONMENTAL BISPHENOL A EXPOSURE ON TRAINED IMMUNITY-RELATED PATHWAYS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A PRELIMINARY OBSERVATION23
OC.09.5 LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN’S DISEASE: A MULTICENTER REALLIFE STUDY23
T.05.10 CLINICAL HETEROGENEITY OF ADULT COELIAC DISEASE ACCORDING TO THE AGE AT ONSET: AN ITALIAN MULTICENTRIC STUDY23
AF.11 BLACK ESOPHAGUS AND SEPTIC SHOCK IN ELDERLY PATIENT: A CASE REPORT22
T.04.6 EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE FOR COLONOSCOPY ON ADENOMA AND POLYP MISS RATE: A METAANALYSIS OF TANDEM RCTS22
AF.33 COMPLIANCE ASSESSMENT TO MICRONUTRIENT SUPPLEMENTATION AFTER BARIATRIC SURGERY: RESULTS FROM AN ITALIAN INTERNET-BASED SURVEY21
T.10.4 INTESTINAL ULTRASONOGRAPHY PROFILING OF PATIENTS WITH CROHN'S DISEASE PREDICTS LONG TERM CLINICAL REMISSION21
AF.70 COLONOSCOPY IN DIVERTICULAR DISEASE BLEEDING: WHEN AND HOW TO DO IT21
T.04.1 EUS-GUIDED GASTROENTEROSTOMY VERSUS ENTERAL STENTING FOR FRAILER PATIENTS WITH MALIGNANT GASTRIC OUTLET OBSTRUCTION: A MATCHED PROSPECTIVE COMPARISON21
AF.66 VEDOLIZUMAB INDUCED LIVER INJURY: A RARE BUT MEANINGFUL CONDITION21
T.12.1 A LATE HEMATOMA AFTER ENDOSCOPIC FULL-THICKNESS RESECTION OF THE APPENDICEAL ORIFICE: WHAT WE SHOULD LEARN FROM PREOPERATIVE ANATOMICAL ASSESSMENT: A CASE REPORT20
T.11.7 THE PROGNOSTIC ROLE OF RADIOMICS IN GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMORS20
AF.77 IRRITABLE BOWEL SYNDROME AND WORK ABILITY IN HEALTH WORKERS EXPOSED TO OCCUPATIONAL STRESS20
AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB20
AF.83 USEFULNESS OF ELASTOMETRY IN EVALUATING THE EXTENTS OF LIVER FIBROSIS AND RISK OF NON HEPATIC COMPLICATION IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN DIABETIC PATIENTS TYPE 2 (DM2)20
AF.98 ERCP THROUGH SURGICAL GASTROSTOMY IN PATIENTS WITH PREVIOUS GASTRIC BY-PASS: A CASE REPORT20
T.11.10 PERFORMANCE OF DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY IN THE VISUAL INTERPRETATION OF INDETERMINATE BILIARY STRICTURES: RESULTS FROM A SINGLECENTER RETROSPECTIVE REAL-LIFE STUDY20
AF.82 THE ROLE OF THE PNPLA3, TM6SF2 AND MBOAT7 GENETIC VARIANTS IN THE RESPONSE TO NUTRACEUTICAL THERAPY FOR NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS20
AF.112 ENDOROTOR-BASED ENDOSCOPIC NECROSECTOMY IN COMPLICATED WALLED-OFF PANCREATIC NECROSIS: A CASE REPORT19
AF.113 OUTCOMES IN EFTR WITH FTRD-SYSTEM: WHEN PATIENT SELECTION IS CRUCIAL19
V.02.2 ENDOSCOPIC TREATMENT OF GASTRIC PERFORATION, BILIODIGESTIVE ANASTOMOSIS DEHISCENCE AND JEJUNAL STUMP LEAK AFTER RADICAL PANCREATECTOMY19
AF.111 AUGMENTED REALITY APPLIED TO DIGESTIVE ENDOSCOPY19
AF.100 RITUXIMAB FOR INDUCTION OF REMISSION IN IGG4-RELATED PANCREATO-BILIARY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS19
V.01.4 ENDOSCOPIC TREATMENT OF ANASTOMOTIC STENOSIS IN A WOMAN WITH MARSUPIALIZATION FOR GASTRO-DUODENAL DUPLICATION AND PANCREAS DIVISUM19
T.12.8 GENDER IMPACT TO ENDOSCOPIC SLEEVE GASTROPLASTY OUTCOMES19
V.01.7 COMPLETE INTRA-PERITONEAL MALDEPLOYMENT OF A LAMS DURING EUS-GEA FOR MGOO: RESCUE RETRIEVAL WITH PERITONEOSCOPY THROUGH NOTES19
AF.146 RADIAL EUS: READY FOR RETIREMENT?18
AF.144 EUS-GASTROENTERO ANASTOMOSIS IN BENIGN GASTRIC OUTLET OBSTRUCTION DUE TO LARGE DUODENAL DIVERTICULA18
AF.145 LINEAR EUS ACCURACY IN GASTRIC CANCER PREOPERATIVE STAGING: A RETROSPECTIVE MULTICENTRIC STUDY18
AF.139 PERFORMANCE OF EUS-GUIDED MOSE-AIDED TISSUE ACQUISITION FOR STRICTURES OF THE COMMON BILE DUCT18
AF.142 ADEQUACY OF EUS-FNB WITH MACROSCOPIC ON-SITE EVALUATION (MOSE) FOR GI SUBEPITHELIAL LESIONS: ARE TWO NEEDLE PASSES ENOUGH?18
AF.128 ENDOSCOPIC MUCOSAL RESECTION (EMR) AND ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) IN THE MANAGEMENT OF LARGE (≥20 MM) NON-PEDUNCOLATE COLORECTAL LESIONS (LNPCLS): EXPERIENCE FROM AN ITALIAN REFERRA18
Inhibition of the Extracellular Signal-Regulated Kinase ERK5 induces an increased expression of the Epidermal Growth Factor receptor and sensitizes hepatocarcinoma cells to gefitinib17
AF.156 PERFORMANCE OF HOT-SPAXUSTM IN TREATING ACUTE AND CHRONIC CHOLECISTITIS: A RETROSPECTIVE MULTICENTER STUDY17
Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies17
OC.07.8 EUS-GUIDED ILEAL-ASCENDING COLON ANASTOMOSIS WITH WATER-FILLED TECHNIQUE FOR PALLIATION OF CIECAL COLON CANCER INVADING THE ILEO-CIECAL VALVE17
De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort17
Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model17
Prevalence of HCV infection in a nursing home: the unknown submerged population16
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study16
Stereotactic body radiation therapy (SBRT) for HCC treatment: a single institution experience16
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis16
Steroidomic profiles across the spectrum of liver damage in non-alcoholic fatty liver disease16
Application of Machine Learning Model-3P to Predict Portal Hypertension in Patient with Hepatocellular Carcinoma16
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy16
Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis16
A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis16
The impact of metabolic risk factors on gender differences in HCC development and treatment allocation16
The impact of bacterial infections on cirrhosis complications in a cohort of cirrhotic patients in a northern Italian hospital16
Diagnostic and prognostic role of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and acute kidney injury15
Does HLA-G play a role in PBC?15
Irisin alleviates liver oxidative stress in non-obese, non-diabetic individuals with Non-Alcoholic Fatty Liver Disease15
A new high-throughput HBV integration sequencing approach shows that mitochondrial DNA is frequently targeted by virus integration in liver cells with active HBV replication15
Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis15
Nash up, virus down: how is changing the waiting list for liver transplantation: a single center experience from Italy15
The IMPROVEMENT project: first report of the global liver transplant activity15
Hepatic sarcoidosis:an Italian multicenter study15
Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis15
Cholestasis impacts on performance of non invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease14
Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of soluble mediators by circulating monocytes14
Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network14
Liposomal doxorubicin targeted with the Fab' of atezolizumab as a novel strategy against HCC14
Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy14
Changes in mean arterial pressure are inadequate to guide treatment with terlipressin and albumin in patients with hepatorenal syndrome - acute kidney injury14
Impact of acute on chronic liver failure (aclf) superimposed to alcoholic cirrhosis: a single centre experience14
OC-02Activation of Liver X Receptor-α in the gut protects against liver injury in nonalcoholic steatohepatitis (NASH)14
Outcomes of Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced hepatocellular carcinoma in the era of immunotherapy: A real-life comparison with best supportive care14
Impact of laparoscopic liver resection for access to the waiting list of a single regional liver transplant center in southern Italy: entry and dropout flows’ analysis14
Safety and Effectiveness of anticoagulation in patients with cirrhosis listed for liver transplantation: a single center observational study14
A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine14
Impact of ISO score on oncological outcomes and survival in liver transplant candidates with hepatocellular carcinoma14
Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model13
Prevalence and clinical outcomes of different forms of renal dysfunction in patients hospitalized for decompensated cirrhosis: focus on acute kidney disease. A prospective observational study13
T.04.5: COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOWED NO DIFFERENCES IN IMMUNOGENICITY OR TREATMENT PERSISTENCE AT ONE YEAR13
V.01.4: TRANSSTOMAL EUS-GUIDED ILEOCOLOSTOMY FOR RELIEF OF MALIGNANT SMALL-BOWEL OBSTRUCTION13
MerTK-expressing macrophages promote the malignant features of cholangiocarcinoma cells13
Tiny but powerful: platelets behaviour in metabolic dysfunction-associated steatotic liver disease and its evolution to liver cirrhosis13
Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study13
T.04.4: CLINICAL OUTCOME AFTER CROHN'S DISEASE-RELATED SURGERY DIFFERENT FROM ILEO-COLONIC RESECTION13
H. PYLORI INFECTION AFFECTS THE HER2-CDH1 INTERACTION13
Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study13
Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD13
LncRNA ILF3-AS1 promotes cell migration, invasion and EMT process in hepatocellular carcinoma via the miR-628–5p/MEIS2 axis to activate the Notch pathway13
Trends in the age-related incidence of colon and rectal cancers in China, 2005–201513
Returning to endoscopy normality through the support of a new non-invasive faecal test based on microbial signatures13
Editorial Board13
V.05.1: EUS-GUIDED FINE NEEDLE BIOPSY OF A DUODENAL GIST: A CHALLENGE FOR ENDOSONOGRAPHERS12
T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK12
T.12.2: THE LEVELS OF AFP, PIVKA-II AND GPC-3 SERUM BIOMARKERS AT DIAGNOSIS CORRELATE WITH HCC CLINICAL-PATHOLOGICAL FEATURES AND WITH OVERALL SURVIVAL12
T.09.3: HIGH RESOLUTION MANOMETRY ASSESSMENT IN EROSIVE REFLUX DISEASE12
T.11.1: MICRONUTRIENT NUTRITIONAL DEFICIENCIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN REMISSION FOLLOWING A LONG-TERM BIOLOGIC TREATMENT12
OC.07.10: SARCOPENIA IS A RISK FACTOR OF POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE12
BOC.04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY12
V.05.4: STENT-IN-STENT ANCHORED WITH METALLIC CLIPS TO TREAT RECURRENCE OF NEOPLASTIC ESOPHAGEAL STENOSIS12
T.07.10: BACTERIAL AND FUNGAL INFECTIONS INACLF: PREVALENCE AND IMPACT ON PATIENT MORBIDITY AND MORTALITY12
V.01.1: EUS-HEPATICODUODENOSTOMY WITH LAMS FOR RECANALIZATION OF A ROUX-EN-Y HEPATICOJEJUNOSTOMY STENOSIS12
V.02.1: KNIFE-ASSISTED INCISION FOR RESTORING ESOPHAGEAL LUMEN AFTER SURGICAL EXCLUSION12
OC.11.1: UNDERDILATION STRATEGY FOR TIPS PLACEMENT REDUCES INCIDENCE OF OVERT HEPATIC ENCEPHALOPATHY WITHOUT AFFECTING CLINICAL EFFICACY AND SURVIVAL: RESULTS OF A MULTICENTER PROSPECTIVE ITALIAN STUD12
OC.09.1: EFFICACY AND SAFETY OF HYBRID ARGON PLASMA COAGULATION TECHNIQUE IN PATIENTS WITH BARRETT'S ESOPHAGUS-RELATED DYSPLASIA: AN ITALIAN MULTICENTER PROSPECTIVE STUDY INITIAL RESULTS12
OC.01.3: EVENING CHRONOTYPE CORRELATES WITH SEVERITY OF FUNCTIONAL DYSPEPSIA AND AFFECT SLEEP QUALITY12
T.01.2: DISTINCT PATHOPHYSIOLOGICAL AND THERAPEUTIC OUTCOME PATTERNS CHARACTERIZE PATIENTS WITH DOMINANT HEARTBURN, REGURGITATION OR CHEST PAIN12
OC.09.5: INCIDENTAL ENDOSCOPIC REMOVAL OF A RECTAL NEUROENDOCRINE TUMOR: WHAT TO DO?12
T.03.8: TIMING OF LUMEN-APPOSING METAL STENTS REMOVAL IN PANCREATIC FLUID COLLECTIONS: COULD WE GO BEYOND?12
OC.04.9: PROMOTION OF PHYSICAL ACTIVITY WITH A MOBILE APP IS SUPERIOR TO PRESCRIPTION ALONE IN IMPROVING SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A RANDOMIZED CONTROLLED TRIAL12
BOC.04.1: ANALYSIS OF IMMUNOLOGICALVARIABLES IN EX VIVO TOFACITINIB-TREATED HUMAN BIOPSIES FROM ACTIVE ULCERATIVE COLITIS PATIENTS TO PREDICT CLINICAL RESPONSE (THE AVATAR STUDY)11
T.11.9: BIOLOGICAL THERAPIES IN THE ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SINGLE-CENTER EXPERIENCE11
T.12.6: HHV8-NEGATIVE EFFUSION-BASED LARGE B-CELL LYMPHOMA (EB-LBCL): A RARE CAUSE OF DIARRHEA AND ASCITES11
V.02.8: CASE REPORT: DIEULAFOY'S LESION DETECTION TRICKS AND TREATMENT11
OC.02.4: SMALL-BOWEL CANCER SURVEILLANCE WITH CAPSULE ENDOSCOPY IN A LARGE COHORT OF LYNCH SYNDROME PATIENTS FOR 20 YEARS11
OC.04.5: ARTIFICIAL INTELLIGENCE AND COLORECTAL NEOPLASIA DETECTION PERFORMANCES IN FIT+ PATIENTS: A METAANALYSIS AND SYSTEMATIC REVIEW11
OC.03.3: CAN CHAT GENERATIVE PRE-TRAINED TRANSFORMER (CHATGPT) BE AN AI-PROVIDED FRIEND OF THE IBD PATIENTS FOR FREQUENTLY ASKED QUESTIONS RELATED TO THEIR DISEASE MANAGEMENT? AN EVIDENCE- AND GUIDELI11
OC.17.2: ERIC, NEW VIRTUAL ASSISTANT FOR COLONOSCOPY: A PILOT STUDY11
OC.15.5: POLIPROTECT IS AN EFFECTIVE TREATMENT TO MANAGE PPI DEPRESCRIBING. A RANDOMIZED CONTROLLED TRIAL (RCT) POST HOC ANALYSIS11
OC.10.1: TOTALLY RETROGRADE ENDOSCOPIC THERAPY TO TREAT STRASBERG TYPE C BILE LEAKS: A RETROSPECTIVE SINGLE CENTER EXPERIENCE11
OC.12.3: SAFETY AND EFFICACY OF MUSCULAR-TUNNELING PERORAL ENDOSCOPIC SEPTOTOMY (MT-POES) FOR THE TREATMENT OF ZENKER'S DIVERTICULUM11
OC.03.8: EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN'S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL11
T.11.6: QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON EXPERIMENTALTRIAL: ATERTIARY SINGLE-CENTER EXPERIENCE11
OC.02.8: ENDOSCOPIC SLEEVE GASTROPLASTY: CAN WE PREDICT ITS EFFICACY AT AN EARLY STAGE?11
OC.05.7: CHOLESTASIS IMPACTS ON PERFORMANCE OF NON INVASIVE TESTS FOR RULING OUT HIGH-RISK ESOPHAGEALVARICES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE11
OC.08.4: ARTIFICIAL INTELLIGENCE TOOLS PREDICT EOSINOPHILIC ESOPHAGITIS IN ADULTS REPORTING DYSPHAGIA: DEVELOPMENT, EXTERNALVALIDATION, AND SOFTWARE CREATION FOR POINT-OF-CARE USE11
T.06.3: PREVALENCE OF, AND MICROBIAL RISK FACTORS FOR, IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA AFTER ACUTE GASTROINTESTINAL INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS11
OC.16.12: PERFORMANCE EVALUATION OF HEPATIC VENOUS PRESSURE GRADIENT (HVPG) SCORE AS PREDICTOR TOOL OF LIVERRELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE11
OC.13.1: PREVENTABLE FACTORS OF POST-COLONOSCOPY COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS11
OC.07.1: CROHN'S DISEASE PATIENTS WITH USTEKINUMAB-INDUCED REMISSION ARE CHARACTERIZED BY HIGH BASELINE P35 CYTOKINES SUBUNITS IN LPMC AND HIGH IL-23 RECEPTOR EXPRESSION IN THE LAMINA PROPRIA TH1 CELL11
T.09.6: VALUE OF MULTIDETECTOR COMPUTED TOMOGRAPHY ANGIOGRAPHY IN SEVERE NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A RETROSPECTIVE STUDY IN A REFERRAL BLEEDING UNIT10
T.06.9: PT1 CANCER OF THE COLON AND RECTUM (CCR): RETROSPECTIVE EVALUATION AND FOLLOW-UP IN REAL PRACTICE10
OC.18.12: THE OUTPATIENT MANAGEMENT IN GASTROINTESTINAL BLEEDING REDUCES THE RE-BLEEDING DURING THE TIME: A COHORT OBSERVATIONAL STUDY10
V.01.8: HEPATIC FASCIOLIASIS: A RARE CASE OF “FAKE” BILIARY GALLSTONES10
Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma10
Jejunal gastrointestinal stromal tumor with rectal lymph nodes metastases synchronous to intestinal adenocarcinoma: a possible common origin10
T.08.7: THE EFFECTIVENESS OF THE ULCA QUESTIONNAIRE IN THE EVALUATION OF GASTROINTESTINAL INVOLVEMENT IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS10
BOC.02.1: EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION: A 10-YEAR EXPERIENCE OF A LARGEVOLUME FMT CENTER10
V.03.4: ENDOSCOPIC “UNROOFING” OF AN INTESTINAL LIPOMA10
V.02.5: THE APOLLO OVERSTITCH SUTURING SYSTEM IS THE LAST CHANCE FOR RECTAL BLEEDING AFTER COMPLICATED ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD)10
Changes in imaging features of immunoglobulin G4-related sclerosing cholecystitis10
V.01.7: A LAPAROSCOPIC AND ENDOSCOPIC COOPERATIVE SURGERY (LECS) APPROACH FOR TREATMENT OF APPENDICEAL LESION IN PATIENTS WITH SERRATED POLYPOSIS SYNDROME (SPS)10
OC.16.10: FATTY LIVER IN IBD PATIENTS: FINDINGS FROM AN OBSERVATIONAL RETROSPECTIVE CROSS-SECTIONAL STUDY10
V.04.5: OVER THE SCOPE CLIPS: A RESCUE THERAPY FOR DUODENAL PERFORATION DUE TO BILIARY STENT MIGRATION10
OC.08.3: DUPILUMAB EFFICACY IN EOSINOPHILIC ESOPHAGITIS PERSISTS FOR HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC OUTCOMES REGARDLESS OF CONCOMITANT HIGH-DOSE PROTON PUMP INHIBITOR USE10
Venous hepatic aneurysms10
Does interval time between liver transplant and COVID-19 infection make the difference?10
AF.41 THE PROGNOSTIC VALUE OF ENDOSCOPIC MAYO SCORE 0 VERSUS 1 IN PATIENTS WITH ULCERATIVE COLITIS IN STEROID-FREE CLINICAL REMISSION: A SYSTEMATIC REVIEW AND METAANALYSIS9
OC.04.5 DISEASE ACTIVITY PATTERNS IN THE FIRST 5 YEARS AFTER DIAGNOSIS IN CHILDREN WITH CROHN'S DISEASE: A POPULATION-BASED STUDY9
AF.45 IBUS-SAS FOR CROHN’S DISEASE ULTRASOUND ACTIVITY: INITIAL VALIDATION AND RESEARCH OF THE OPTIMAL CUT-OFF SCORE9
OC.10.3 INCREASED INTESTINAL PERMEABILITY IN CROHN'S DISEASE PATIENTS TREATED WITH TEDUGLUTIDE FOR SHORT BOWEL SYNDROME: PARADOXICAL OR BENEFICIAL EFFECT?9
OC.03.8 SAFE AND EFFICACY OF SINGLE CENTRAL ENDOSCOPIC ULTRASOUND GUIDED NEUROLYSIS OF CELIAC PLEXUS FOR PAIN RELIEF IN UNRESECTABLE PANCREATIC CANCER PATIENTS9
OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA 9
OC.04.1 SURGERY IN HIGH-RISK PAEDIATRIC CROHN'S DISEASE TREATED WITH UP-FRONT ANTI-TNF AGENTS AND LONG-STANDING BIOLOGIC THERAPY9
AF.3 QUALITY OF LIFE IN PATIENTS COMPLAINING OF UPPER GASTROINTESTINAL SYMPTOMS: A NATIONAL SURVEY IN PATIENTS ATTENDING GASTROENTEROLOGY CLINICS OF THE ITALIAN NHS: AN INTERIM ANALYSIS OF THE GUESS S9
Verona liver day: Data of liver health from the Arena9
AF.7 USE OF PURASTAT® FOR POST-SPHINCTEROTOMY BLEEDING REFRANTORY TO SELF-EXPANDABLE METALLIC STENT (SEMS) PLACEMENT: A CASE REPORT9
AF.43 SOCIAL FUNCTIONING, WORK-PRODUCTIVITY AND PSYCHOLOGICAL ASSESSMENT IN A COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL STUDY9
T.05.5 A COMPARISON OF PCA-POSITIVE VS PCA-NEGATIVE AUTOIMMUNE ATROPHIC GASTRITIS PATIENTS9
OC.12.5 MYOSTEATOSIS IS NOT ASSOCIATED WITH COMPLICATIONS OR SURVIVAL IN HCC PATIENTS UNDERGOING TRANS ARTERIAL EMBOLIZATION9
Psychological profiles and risk of relapse in cirrhosis due to alcohol abuse9
Individualized HBIG withdrawal in an historical cohort of liver transplant recipients in Italy9
T.01.7 VACCINATION STATUS AND ATTITUDES TOWARDS VACCINES IN A COHORT OF PATIENTS WITH CELIAC DISEASE9
OC.03.9 SPARING SPLENIC ARTERY: RADIOLOGICAL-ASSISTED DIRECT ENDOSCOPIC NECROSECTOMY USING ENDOROTOR9
How macronutrients and pancreatic enzyme supplements dose variability affect fat, protein and starch absorption in children with cystic fibrosis9
Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs)9
T.03.3 THE INFLUENCE OF SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) LIFESTYLE CHANGES ON NON-ALCOHOLIC FATTY LIVER DISEASE EVOLUTION: A MATTER OF BODY COMPOSITION: A MULT9
OC.03.2 BILIOPANCREATIC ADVERSE EVENTS AFTER PANCREATICODUODENECTOMY: PRELIMINARY RESULTS OF ENDOSCOPIC MANAGEMENT WITH PEDIATRIC COLONOSCOPE9
AF.50 SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY9
AF.38 SHORT BOWEL SYNDROME IN ITALY, YET UNDERESTIMATED AND IN NEED OF INCREASED AWARENESS: PRELIMINARY REPORT FROM AN AIGO SURVEY9
OC.04.7 LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PBC FROM THE POISE TRIAL GROUPED BIOCHEMICALLY BY RISK OF DISEASE PROGRESSION9
OC.12.6 SINGLE-USE DUODENOSCOPES IN EXTREME CONDITIONS: ERCP IN LIVER TRANSPLANTED PATIENTS9
AF.61 PROSPECTIVE, OBSERVATIONAL STUDY OF PROPHYLACTIC VEDOLIZUMAB TREATMENT IN PREVENTING POSTOPERATIVE RECURRENCE (POR) IN HIGH-RISK CROHN’S PATIENTS9
OC.02.4 WHEN ACHALASIA PATIENTS RELAPSE AFTER LAPAROSCOPIC MYOTOMY, COMPLEMENTARY PNEUMATIC DILATIONS REPRESENT AN EFFECTIVE AND SAFE TREATMENT9
OC.04.3 FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS9
General Practitioner databaSe NAFLD (GPS-NAFLD) study: Italian regional variability of the NAFLD prevalence rate9
AF.16 DIAGNOSTIC DELAY AND MISDIAGNOSIS IN EOSINOPHILIC ESOPHAGITIS9
Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: A single-center experience9
OC.09.4 PREVALENCE OF NAFLD (NON ALCOHOLIC FATTY LIVER DISEASE) IN INFLAMMATORY BOWEL DISEASE: THE ROLE OF METABOLIC FACTORS, INTESTINAL INFLAMMATION AND GENETIC PHENOTYPE9
OC.05.7 BLINDED ORAL CHALLENGES WITH LACTOSE AND PLACEBO ACCURATELY DIAGNOSE LACTOSE INTOLERANCE: A REAL-LIFE STUDY9
T.01.6 THE EFFICACY OF SIX-FOOD ELIMINATION DIET IS LOWER DURING POLLEN SEASON IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS SENSITIZED TO POLLENS8
OC.02.3 DEVELOPING AND VALIDATING A DEATH SCORE RISK IN NONVARICEAL UPPER GI BLEEDING PATIENTS (RE.CO.DE SCORE): A PROSPECTIVE MULTICENTER COHORT STUDY8
PC.01.7 SAME-SESSION DOUBLE EUS-BYPASS VERSUS SURGICAL GASTROENTEROSTOMY AND HEPATICOJEJUNOSTOMY: AN INTERNATIONAL MULTICENTER COMPARISON8
Impact of complications on long-term survival after pediatric liver transplantation8
Epidemiological and clinical profile of HDV infected people in care in Italy: Interim analysis from the ongoing PITER cohort8
A functional interaction between hepatic estrogen receptor-α and PNPLA3 p.I148M inherited variant drives fatty liver disease susceptibility in women8
Fatty Acid Synthase expression promotes the malignant features of cholangiocarcinoma cells and predicts shorter survival in patients8
OC.01.1 IMPROVED SURVIVAL FOR PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING WHILE ON ANTI-THROMBOTIC THERAPY: A MULTICENTER PROSPECTIVE COHORT STUDY8
OC.07.5 ENDOSCOPIST SESSILE SERRATED POLYP DETECTION RATE AND INCIDENT POST-COLONSCOPY COLORECTAL CANCER8
T.01.11 AN RC TRIAL COMPARING THE MUCOSAL PROTECTIVE AGENT (MPA) POLIPROTECT (NEOBIANACID®) (P) AND OMEPRAZOLE (O) IN THE TREATMENT OF HEARTBURN AND EPIGASTRIC PAIN/BURNING IN NON-EROSIVE REFLUX DISEA8
OC.06.4 DEMOGRAPHIC DIFFERENCES IN LEFT-TO-RIGHT SHIFT OF COLON CANCER OVER 25 YEARS: RESULTS FROM ROBUST ANALYSIS OF CANCER REGISTRY DATA8
Hepatocellular carcinoma prognostic scores: A 10 years experience8
Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single regional reference center report8
HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling8
The rs1468615 T>C in ABCB4 confers protection against gallstone disease but not against severe liver disease8
Patient-derived liver organoids as an in vitro model to study new personalized therapies targeting VDAC1 in intrahepatic cholangiocarcinoma8
Salivary Analytical Device (SAD), a good tool for monitoring the metabolic status of patients with fatty liver disease8
OC.01.8 ESOPHAGEAL RIGHT BRONCHIAL ARTERY FISTULA: AN EXTRAORDINARY RARE CAUSE OF MASSIVE UPPER GASTROINTESTINAL BLEEDING FOLLOWING PALLIATIVE ESOPHAGEAL METALLIC STENTING8
OC.09.5 ALTERNATION OF MRI AND EUS IN PANCREATIC CANCER SCREENING COULD INCREASE DETECTION OF BOTH PANCREATIC AND EXTRA-PANCREATIC FINDINGS8
AFP at transplant is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria8
OC.06.2 ULTRASOUND EVALUATION OF PELVIC FLOOR DYNAMIC IN CONSTIPATED PATIENTS: A NEW APPROACH TO DIAGNOSE FUNCTIONAL DEFECATION DISORDERS8
OC.03.1 URGENT ERCP WITH SPHINCTEROTOMY VERSUS CONSERVATIVE TREATMENT IN THE MANAGEMENT OF ACUTE BILIARY PANCREATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS8
Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes a pro-tumorigenic inflammatory response8
Pregnancy after liver transplantation: a survey from Italian liver transplants centres8
Prognostic value of simple non-invasive tests for the risk stratification of hcc development in patients with cirrhosis due to non-alcoholic fatty liver disease8
Validation of a targeted gene panel sequencing for the diagnosis of hereditary chronic liver diseases8
B-Klotho deficiency in hepatic stellate cells (HSCs) prompts inflammation, oxidative stress and a pro-fibrotic phenotype8
OC.06.5 HIGH SMAD7 MARKS INFLAMMATION IN PATIENTS WITH CHRONIC POUCHITIS8
PC.01.1 LAPAROSCOPIC VERSUS EUS-GUIDED GASTROENTEROSTOMY FOR GASTRIC OUTLET OBSTRUCTION: AN INTERNATIONAL MULTICENTER PROPENSITY SCORE-MATCHED COMPARISON8
The impact of a local antibiotic stewardship program: Low rate of spontaneous bacterial peritonitis and bacteriascites sustained by multidrug-resistant organisms8
Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review8
OC.12.4 EXCEEDING TREATMENT EXPECTATIONS IN CROHN’S DISEASE: TRANSMURAL HEALING AND A NEW DEFINITION OF DEEP REMISSION7
T.07.8 GASTRO-INTESTINAL (GI) AND LIVER COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): AN INVESTIGATION ON THE INCIDENCE AND RISK FACTORS IN THE EXPERIENCE OF OUR 7
Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region7
OC.09.1 FEASIBILITY OF DNA EXTRACTION AND MOLECULAR PROFILING FROM EUS-BIOPSY OF PANCREATIC CANCER7
OC.07.4 PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS ARE AT RISK OF GASTRIC NEOPLASTIC LESIONS AT LONG-TERM FOLLOW UP DESPITE LOW RISK PROGNOSTIC SCORES7
T.08.8 IMPACT OF METFORMIN ON THE INCIDENCE OF HUMAN CHOLANGIOCARCINOMA IN DIABETIC PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS7
OC.06.1 PAN-ENTERIC CAPSULE ENDOSCOPY TO CHARACTERIZE CROHN’S DISEASE PHENOTYPES AND PREDICT CLINICAL OUTCOMES IN CHILDREN AND ADULTS7
T.07.1 ALTERATIONS OF GUT MICROBIOTA IN FUNCTIONAL DIARRHEA - A RETROSPECTIVE SINGLE-CENTER STUDY7
OC.11.4 CAN THE LONDON CLASSIFICATION BE USED TO PERFORM AND ANALYZE HIGH DEFINITION 3D ANORECTAL MANOMETRY?7
OC.11.5 IMPACT OF REFLUX BURDEN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY ACCORDING TO THE CRITERIA PROPOSED BY CCV4.0 COMPARED TO CCV3.07
OC.07.2 ZINC L-CARNOSINE EXERTS ANTI-INFLAMMATORY EFFECTS EX VIVO IN HUMAN AUTOIMMUNE ATROPHIC GASTRITIS7
OC.08.5 THE EFFECTS OF LONG-TERM PROTON PUMP INHIBITOR THERAPY ON GUT MICROBIOTA - A SINGLE-CENTER EXPERIENCE7
PC.01.8 MAFLD VS NAFLD: THE IMPLICATIONS FOR THE NOMENCLATURE CHANGE7
PC.01.7 EUS-GUIDED FINE-NEEDLE BIOPSY OF SOLID LESIONS WITH OR WITHOUT MACROSCOPIC ON-SITE EVALUATION (MOSE): A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL7
OC.11.3 LAPAROSCOPIC HELLER DOR IS AN EFFECTIVE TREATMENT FOR ESOPHAGEAL-GASTRIC JUNCTION OUTFLOW OBSTRUCTION7
OC.07.5 AUTOIMMUNE ATROPHIC GASTRITIS IN COELIAC DISEASE: ARE THERE ANY DISTINCTIVE FEATURES?7
OC.06.5 EVALUATION OF TOLERABILITY OF “ANCIENT” GRAINS IN NCGS PATIENTS7
0.083499908447266